ClinicalTrials.gg
CompletedNCT00413972Updated Feb 9, 2022Results posted

Effects of Vytorin Versus Placebo in Subjects With Primary Hypercholesterolemia (Study P04420)

A Phase 3 interventional study of ezetimibe with simvastatin and Ezetimibe with Simvastatin in Hypercholesterolemia, sponsored by Organon and Co. Completed. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-02-09.

Sponsored by Organon and Co · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
392
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies testing ezetimibe in Hypercholesterolemia — 3 open to participants now, 4 under way, 1 of them phase 3. Ezetimibe · Hypercholesterolemia.

Enrollment
23rd of 97
392 · median 148
Started
2006
with 5 others
Phase 3
50 of 98
1 open now
Registered
19th of 98
by date
Lead sponsor
55 of 98
Organon and Co

Among the 98 studies testing ezetimibe in Hypercholesterolemia, this one is the 23rd largest by enrollment of the 97 interventional ones that give a count, is one of 6 that started in 2006, is one of 50 in phase 3, and was the 19th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

3 of the 98 studies testing ezetimibe in Hypercholesterolemia are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ezetimibe

Ezetimibe: first FDA approval 2002 (ZETIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies testing ezetimibe in Hypercholesterolemia, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase 3 study of Vytorin 10/10 (ezetimibe 10 mg with simvastatin 10 mg), Vytorin 10/20 (ezetimibe 10 mg with simvastatin 20 mg), and Vytorin 10/40 (ezetimibe 10 mg with simvastatin 40 mg) compared to placebo administered daily for 8 consecutive weeks in subjects with primary hypercholesterolemia (LDL-C >3.64 mmol/L [140 mg/dL]). The efficacy of daily Vytorin versus placebo in reducing the concentration of LDL-C will be evaluated, and the efficacy of daily Vytorin versus placebo with respect to change in the concentrations of total cholesterol, triglycerides, and HDL-C will be compared. The safety of Vytorin versus placebo will also be assessed.

03

Conditions studied

  • Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must be >=18 years and \<=75 years of age, male or female.
  • Primary hypercholesterolemic subject with a plasma LDL cholesterol concentration >3.64 mmol/L (140 mg/dL) to \<=6.3 mmol/L (250 mg/dL) using the Friedewald calculation; total cholesterol (TC) >5.2 mmol/L (200 mg/dL) to \<12.7 mmol/L (500 mg/dL) and triglyceride concentrations of \<=3.99 mmol/L (350 mg/dL) should be met at the same time. At the time of recruitment (Visit 1), these values may be lower if the subject is on lipid-lowering therapy. (ie, prior to the start of lipid lowering drug ) or may be higher at the start of dietary therapy.
  • Liver transaminases (, AST) \<=50% above the , with no active liver disease and CK \<=50% above the upper limit of normal.
  • Clinical laboratory tests (complete blood count [CBC], blood chemistries, urinalysis) must be within normal limits, or clinically acceptable to the investigator/sponsor.
  • Women of (includes women who are less than 1 year and women who become sexually active) must be using an acceptable method of .
  • Subjects must be free of any diseases other than hyperlipidemia that would interfere with study evaluations.
  • Subjects must understand and be able to adhere to the dosing and visit schedules.
  • Subject must agree to remain on a cholesterol-lowering diet for the duration of the study (according to China Adult Treatment Panel of High Blood Cholesterol).

Exclusion criteria

Exclusion Criteria:

  • Subjects whose (BMI=weight [kg]/height2 [m]) is >=30 kg/m2 at Visit 3 (Baseline Visit).
  • Subjects who have known to HMG CoA reductase inhibitors.
  • Subjects who consume >14 alcoholic drinks per week. (A drink is: a can of beer, glass of wine, or single measure of spirits).
  • Any condition or situation, which in the opinion of the investigator, might pose a risk to the subject or interfere with participation in the study.
  • Women who are pregnant or nursing.
  • Subjects who have not observed the designated for any of the prohibited medications.
  • Congestive heart failure defined by as Class III or IV.
  • Uncontrolled cardiac arrhythmia.
  • Myocardial infarction, coronary bypass surgery, or angioplasty within 6 months of study entry.
  • Unstable or severe peripheral artery disease within 3 months of study entry.
  • Unstable angina pectoris within 6 months of study entry.
  • Uncontrolled hypertension (treated or untreated) with systolic blood pressure >160 mm Hg or diastolic >100 mm Hg at study entry.
  • Uncontrolled (as determined by fasting glucose >180 mg/mL or >9%) or newly diagnosed (within 1 month of study entry) diabetes mellitus.
  • Uncontrolled endocrine or metabolic disease known to influence serum lipids or lipoproteins, ie, secondary causes of hyperlipidemia, such as secondary hypercholesterolemia due to hypothyroidism (thyroid stimulating hormone [TSH] above ). Subjects with a history of hypothyroidism who are on a stable therapy of thyroid hormone replacement for at least 6 weeks are eligible for enrollment if TSH levels are within normal limits before enrollment.
  • Known impaired renal function (plasma creatinine >2.0 mg/dL), or nephrotic syndrome at study entry.
  • Disorders of the hematologic, digestive, or central nervous systems, including cerebrovascular disease and degenerative disease that would limit study evaluation or participation.
  • Known positive.
  • Cancer within the past 5 years (except for successfully treated basal and squamous cell carcinomas).
  • History of mental instability, drug/alcohol abuse within the past 5 years, or major psychiatric illness not adequately controlled and stable on pharmacotherapy.
  • Female subject receiving hormonal therapy, including hormone replacement, any estrogen antagonist/agonist, or oral .
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
392 participants (actual)

Study arms

  • Experimental
    Vytorin 10/10

    Ezetimibe 10 mg with Simvastatin 10 mg

    Drug: ezetimibe with simvastatin

  • Experimental
    Vytorin 10/20

    Ezetimibe 10 mg with Simvastatin 20 mg

    Drug: Ezetimibe with Simvastatin

  • Experimental
    Vytorin 10/40

    Ezetimibe 10 mg with Simvastatin 40 mg

    Drug: Ezetimibe with Simvastatin

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Drugezetimibe with simvastatin

    Drug pages: Ezetimibe · Simvastatin

    Ezetimibe 10 mg with Simvastatin 10 mg once daily for a total of eight weeks

  • DrugEzetimibe with Simvastatin

    Drug pages: Ezetimibe · Simvastatin

    Ezetimibe 10 mg with Simvastatin 20 mg once daily for a total of eight weeks

  • DrugEzetimibe with Simvastatin

    Drug pages: Ezetimibe · Simvastatin

    Ezetimibe 10 mg with Simvastatin 40 mg once daily for a total of eight weeks

  • DrugPlacebo

    Placebo once daily for a total of eight weeks

06

What researchers measure

Primary outcomes

  1. Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Endpoint After 8 Weeks of Treatment

    Time frame: Baseline, 8 weeks

07

Results

Posted May 25, 2010

Participant flow

Participant flow — Overall Study
MilestoneVytorin 10/10Vytorin 10/20Vytorin 10/40Placebo
Started98989898
Completed91908895
Not completed78103
Withdrew: Adverse event2100
Withdrew: Lost to follow-up1210
Withdrew: Withdrawal by subject4572
Withdrew: Protocol violation0020
Withdrew: Other0001

Outcome measures

PrimaryPercent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Endpoint After 8 Weeks of Treatment
Time frame:
Baseline, 8 weeks
Reported as:
Mean · percent change of LDL-C
Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Endpoint After 8 Weeks of Treatment
percent change of LDL-CVytorin 10/10Vytorin 10/20Vytorin 10/40Placebo
Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Endpoint After 8 Weeks of Treatment-41.69 ± 2.06-46.83 ± 2.08-49.10 ± 2.07-7.53 ± 2.04
Statistical analysis
  • Vytorin 10/10 vs Placebo · ANOVA · p = <.0001
  • Vytorin 10/20 vs Placebo · ANOVA · p = <.0001
  • Vytorin 10/40 vs Placebo · ANOVA · p = <.0001

Adverse events

Collected over 9 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vytorin 10/10—0/97 (0%)0/97 (0%)
Vytorin 10/20—0/97 (0%)0/97 (0%)
Vytorin 10/40—0/98 (0%)0/98 (0%)
Placebo—0/97 (0%)0/97 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Vytorin 10/10Vytorin 10/20Vytorin 10/40PlaceboTotal
Mean58.2 ± 10.757.4 ± 9.756.4 ± 10.360.2 ± 9.258.2 ± 10.07
Sex: Female, Male
Sex: Female, Male(Participants)Vytorin 10/10Vytorin 10/20Vytorin 10/40PlaceboTotal
Female59616660246
Male38363237143
Region of Enrollment
Region of Enrollment(participants)Vytorin 10/10Vytorin 10/20Vytorin 10/40PlaceboTotal
China97979897389
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2006, a primary completion of Nov 2006 and a completion of Nov 2006. It does not say whether these dates are actual or estimated.

Results were first posted in May 2010, 3 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2006
First posted
Dec 20, 2006
Start
Apr 2006
Primary completionActual
Nov 2006
CompletionActual
Nov 2006
Results first posted
May 25, 2010
Last update
Feb 9, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00413972
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Dec 20, 2006
Start date
Apr 2006
Primary completion
Nov 2006
Completion
Nov 2006
Results posted
May 25, 2010
Last update
Feb 9, 2022
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ezetimibe · Simvastatin

Start the discussion